Aliyah Zaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aliyah Zaman has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Alyson E. Fournier
Department of Neurology and Neurosurgery, Montreal Neurological Institute McGill University Montreal Quebec Canada
2 shared publications Sienna S. Drake
Department of Neurology and Neurosurgery, Montreal Neurological Institute McGill University Montreal Quebec Canada
1 shared publication- Sienna S. Drake
Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC H3A2B4, Canada
1 shared publication - Tristan Simas
McGill University, Montreal Neurological Institute Montreal Quebec Canada
1 shared publication
Latest Publications
- Open Access
- 22 January 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (1) , e70323
Extracellular Vesicle‐Derived microRNAs as Fluid Biomarkers in Neurodegenerative Diseases: A Systematic Review
Given the absence of curative treatments for neurodegenerative diseases, early detection and therapeutic intervention are critical to slowing disease progression. Extracellular vesicles (EVs) have emerged as promising biomarkers for neurodegeneration, owing to their accessibility in bodily fluids and dynamic molecular cargo, including microRNAs (miRNAs). The last decade has seen accumulating evidence for miRNA dysregulation in circulating EVs from people with neurodegenerative diseases; however, assessing reproducibility between studies remains challenging, largely due to clinical and methodological heterogeneity. In this systematic review, we comprehensively searched the MEDLINE database for studies investigating miRNA expression in biofluids from people with neurodegenerative diseases. We extracted miRNA expression data from 185 peer‐reviewed publications, published until June of 2025, reporting altered miRNA levels in fluid‐derived EVs from people with neurodegenerative diseases. We consolidated results between studies to identify the most frequently dysregulated miRNAs across diseases, with a focus on Alzheimer's disease, Parkinson's disease, mild cognitive impairment, multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, stroke, traumatic brain injury, and schizophrenia. Evaluating tissue specificity of frequently dysregulated miRNAs revealed enrichment of select miRNAs in the nervous system relative to blood and immune compartments. Summarizing miRNA regulation across biofluids emphasized consistencies between cerebrospinal fluid and plasma, but not serum. We highlight circulating miRNAs that may be reflective of neuropathology, including miR‐143‐3p, miR‐127‐3p, miR‐9‐5p, miR‐15a‐5p, and miR‐125b‐5p. Finally, we provide a repository of miRNA expression data from over 30 neurodegenerative conditions which can be exploited to further investigate miRNA regulation in diseases of interest. image
- 22 January 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (1) , e70323
Open AccessExtracellular Vesicle‐Derived microRNAs as Fluid Biomarkers in Neurodegenerative Diseases: A Systematic Review
Given the absence of curative treatments for neurodegenerative diseases, early detection and therapeutic intervention are critical to slowing disease progression. Extracellular vesicles (EVs) have emerged as promising biomarkers for neurodegeneration, owing to their accessibility in bodily fluids and dynamic molecular cargo, including microRNAs (miRNAs). The last decade has seen accumulating evidence for miRNA dysregulation in circulating EVs from people with neurodegenerative diseases; however, assessing reproducibility between studies remains challenging, largely due to clinical and methodological heterogeneity. In this systematic review, we comprehensively searched the MEDLINE database for studies investigating miRNA expression in biofluids from people with neurodegenerative diseases. We extracted miRNA expression data from 185 peer‐reviewed publications, published until June of 2025, reporting altered miRNA levels in fluid‐derived EVs from people with neurodegenerative diseases. We consolidated results between studies to identify the most frequently dysregulated miRNAs across diseases, with a focus on Alzheimer's disease, Parkinson's disease, mild cognitive impairment, multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, stroke, traumatic brain injury, and schizophrenia. Evaluating tissue specificity of frequently dysregulated miRNAs revealed enrichment of select miRNAs in the nervous system relative to blood and immune compartments. Summarizing miRNA regulation across biofluids emphasized consistencies between cerebrospinal fluid and plasma, but not serum. We highlight circulating miRNAs that may be reflective of neuropathology, including miR‐143‐3p, miR‐127‐3p, miR‐9‐5p, miR‐15a‐5p, and miR‐125b‐5p. Finally, we provide a repository of miRNA expression data from over 30 neurodegenerative conditions which can be exploited to further investigate miRNA regulation in diseases of interest. image
- 4 January 2023
- Published by Wiley in WIREs Mechanisms of Disease
- Vol. 15 (2) , e1594
Comparing RNA‐sequencing datasets from astrocytes, oligodendrocytes, and microglia in multiple sclerosis identifies novel dysregulated genes relevant to inflammation and myelination
Central nervous system (CNS) inflammation is a key factor in multiple sclerosis (MS). Invasion of peripheral immune cells into the CNS resulting from an unknown signal or combination of signals results in activation of resident immune cells and the hallmark feature of the disease: demyelinating lesions. These lesion sites are an amalgam of reactive peripheral and central immune cells, astrocytes, damaged and dying oligodendrocytes, and injured neurons and axons. Sustained inflammation affects cells directly located within the lesion site and further abnormalities are apparent diffusely throughout normal‐appearing white matter and grey matter. It is only relatively recently, using animal models, new tissue sampling techniques, and next‐generation sequencing, that molecular changes occurring in CNS resident cells have been broadly captured. Advances in cell isolation through Fluorescence Activated Cell Sorting (FACS) and laser‐capture microdissection together with the emergence of single‐cell sequencing have enabled researchers to investigate changes in gene expression in astrocytes, microglia, and oligodendrocytes derived from animal models of MS as well as from primary patient tissue. The contribution of some dysregulated pathways has been followed up in individual studies; however, corroborating results often go unreported between sequencing studies. To this end, we have consolidated results from numerous RNA‐sequencing studies to identify and review novel patterns of differentially regulated genes and pathways occurring within CNS glial cells in MS.This article is categorized under: Neurological Diseases > Molecular and Cellular Physiology
- 4 January 2023
- Published by Wiley in WIREs Mechanisms of Disease
- Vol. 15 (2) , e1594
Comparing RNA‐sequencing datasets from astrocytes, oligodendrocytes, and microglia in multiple sclerosis identifies novel dysregulated genes relevant to inflammation and myelination
Central nervous system (CNS) inflammation is a key factor in multiple sclerosis (MS). Invasion of peripheral immune cells into the CNS resulting from an unknown signal or combination of signals results in activation of resident immune cells and the hallmark feature of the disease: demyelinating lesions. These lesion sites are an amalgam of reactive peripheral and central immune cells, astrocytes, damaged and dying oligodendrocytes, and injured neurons and axons. Sustained inflammation affects cells directly located within the lesion site and further abnormalities are apparent diffusely throughout normal‐appearing white matter and grey matter. It is only relatively recently, using animal models, new tissue sampling techniques, and next‐generation sequencing, that molecular changes occurring in CNS resident cells have been broadly captured. Advances in cell isolation through Fluorescence Activated Cell Sorting (FACS) and laser‐capture microdissection together with the emergence of single‐cell sequencing have enabled researchers to investigate changes in gene expression in astrocytes, microglia, and oligodendrocytes derived from animal models of MS as well as from primary patient tissue. The contribution of some dysregulated pathways has been followed up in individual studies; however, corroborating results often go unreported between sequencing studies. To this end, we have consolidated results from numerous RNA‐sequencing studies to identify and review novel patterns of differentially regulated genes and pathways occurring within CNS glial cells in MS.This article is categorized under: Neurological Diseases > Molecular and Cellular Physiology